Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United KingdomIssue Date
2015-06-08
Metadata
Show full item recordAbstract
The advanced biliary tract cancer (ABC)-02 study established cisplatin and gemcitabine (CisGem) as a reference 1(st)-line regimen for patients with advanced/metastatic biliary tract cancer; patients with bilirubin ⩾1.5 × upper limit of normal (ULN) were excluded and there are few extant data for systemic treatment in the context of elevated bilirubin.Citation
Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. 2015: Eur J CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2015.05.018PubMed ID
26066735Type
ArticleLanguage
enISSN
1879-0852ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2015.05.018
Scopus Count
Collections
Related articles
- A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
- Authors: Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, McEntee D, Sukumaran A, Wasan H, Valle JW
- Issue date: 2016 Feb 24
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
- Authors: Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA
- Issue date: 2015 Aug
- Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
- Authors: Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J, Okusaka T
- Issue date: 2014 Feb
- Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies.
- Authors: Grenader T, Nash S, Plotkin Y, Furuse J, Mizuno N, Okusaka T, Wasan H, Valle J, Bridgewater J
- Issue date: 2015 Sep
- Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
- Authors: Dierks J, Gaspersz MP, Belkouz A, van Vugt JLA, Coelen RJS, de Groot JWB, Ten Tije AJ, Meijer WG, Pruijt JFM, van Voorthuizen T, van Spronsen DJ, Rentinck M, Ten Oever D, Smit JM, Otten HM, van Gulik TM, Wilmink JW, Groot Koerkamp B, Klümpen H
- Issue date: 2018 Jun